How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Christie Ballantyne, MD

Christie Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention Methodist DeBakey Heart Center Chief of the Section of Cardiovascular Research Baylor College of Medicine Director of Atherosclerosis Laboratory Professor of Medicine Baylor College of Medicine Houston, TX